The present study aimed to evaluate the suppressive effect of CDK4/6 inhibitor in combination with endocrine therapy in HR+/HER2-low breast cancer and to explore the specific mechanism by which neratinib improves the efficacy of CDK4/6 inhibitor in combination with endocrine therapy. The gene discussed is ERBB2; the disease is breast carcinoma.